Igarashi et al. first revealed the presence of KRAS (p.G12V) mutation in IPMN and transitional areas rather than NET area, supporting the fourth hypothesis [27]. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.